Difference between revisions of "Capecitabine (Xeloda)"
| Line 11: | Line 11: | ||
*[[Colon cancer]] | *[[Colon cancer]] | ||
*[[Esophageal cancer]] | *[[Esophageal cancer]] | ||
| + | *[[Gastric cancer]] | ||
*[[Hepatobiliary cancer]] | *[[Hepatobiliary cancer]] | ||
| + | *[[Neuroendocrine tumors]] | ||
*[[Pancreatic cancer]] | *[[Pancreatic cancer]] | ||
*[[Rectal cancer]] | *[[Rectal cancer]] | ||
Revision as of 02:47, 23 June 2013
General information
Class/mechanism: Pyrimidine analog, antimetabolite, inhibitor of thymidylate synthase. Converted in vivo to fluorouracil (5-FU), which is metabolized to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits DNA synthesis by binding to thymidylate synthase and inhibiting production of thymidylate; FUTP interferes with RNA processing when it is mistakenly incorporated in place of uridine triphosphate (UTP).[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, [http://www.utdol.com/online/content /search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.[1]
Diseases for which it is used
- Breast cancer
- Colon cancer
- Esophageal cancer
- Gastric cancer
- Hepatobiliary cancer
- Neuroendocrine tumors
- Pancreatic cancer
- Rectal cancer
Patient drug information
- Capecitabine (Xeloda) package insert pages 34-37[1]
- Capecitabine (Xeloda) patient drug information (Chemocare)[4]
- Capecitabine (Xeloda) patient drug information (UpToDate)[5]